N/A N=134 A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.
Peripheral Arterial Disease
Primary: Composite of Major Adverse Events (MAEs) — 2.3 percentage of subjects experiencing MAE — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=141 Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)
Peripheral Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or…
Phase 3 N=153 Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 5.4 percentage of participants
N/A N=155 BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
Peripheral Artery Disease · Peripheral Vascular Disease · Arterial Occlusive Disease
Primary: Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target…
N/A N=75 VISIBILITY™ Iliac Study
Peripheral Arterial Disease · Claudication
Primary: Major Adverse Event Rate at 9 Months — 4.0 percentage of participants
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
N/A N=165 Atrium iCAST Iliac Stent Pivotal Study
Peripheral Vascular Disease
Primary: Percentage of ITT Population Experiencing Death Within 30 Days, Target Site Revascularization or Restenosis — 8.1 Percentage of subjects — p=0.005
N/A N=25 Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
Peripheral Artery Disease · PAD · Claudication
Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR
Phase 3 N=151 Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 6.1 percentage of participants
N/A N=123 The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study
Peripheral Vascular Disease
Primary: Major Adverse Events (MAE), Measured as Device and/or Procedure Related Death, Target Limb Loss and/or Clinically Driven Target Lesion Revascularization (TLR) or Target…
N/A N=64 Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis
Common Iliac Artery Aneurysms · Aorto-iliac Aneurysms
Primary: Freedom From Composite of the Following: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Conversion to Open…
N/A N=100 Chronic Total Occlusion Crossing With the Ocelot System - CONNECT II
Total Atherosclerotic Occlusion of Femoral Artery
Primary: Primary Safety Endpoint — 2 Percent of participants
Phase 4 N=102 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral Arterial Disease
Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…
N/A N=50 The Complete® Self-Expanding Stent and Stent Delivery System Registry
Peripheral Vascular Disease
Primary: The Number of Participants With Major Adverse Events (MAE) — 0 participants
Phase 3 N=2,201 Occluded Artery Trial (OAT)
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) — 230; 219 participants
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
Phase 2 N=46 Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Peripheral Artery Disease (PAD); Intermittent Claudication
Primary: Number of Participants With Adverse Events (AEs), Drug-related AEs, Serious Adverse Events (SAEs) and Deaths — 18; 17; 4; 4 Participants
N/A N=60 Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound
Peripheral Artery Disease
Primary: Change in Minimal Luminal Area — 5.8; 4 mm^2
Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
N/A N=12 Evaluation of Imaging of Peripheral Arteries by Optical Coherence Tomography and Intravascular Ultrasound Imaging
Peripheral Artery Disease
Primary: Visualization of Vessel Morphology: Layered Structure — 1.61; 1.49 score on a scale
N/A N=67 Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II
Peripheral Arterial Disease
Primary: Absolute Claudication Distance (ACD) — 54.374; 0.792 Meters
N/A N=9 Intermittent Pneumatic Compression to Improve Revascularization Outcome
Peripheral Arterial Disease
Primary: Walking Endurance — -14; 35 Meters
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Device Technical Success — 29 lesions
Phase 2 N=20 Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
Critical Limb Ischemia
Primary: Reintervention, Above Ankle Amputation and Restenosis (RAS) — 7; 4 Participants
N/A N=23 Optical Imaging Measurement of Intravascular Solution Efficacy Trial
Peripheral Artery Disease
Primary: Quality of Images — .702; .872; .10; .743 Clear imaging field (CIF) proportion
Phase 3 N=125 EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries
Iliac Artery Stenosis
Primary: Device- and/or Procedure-related Major Adverse Events (MAE) — 3.4 percentage of participants — p=<0.0001
N/A N=134 A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System
Iliac Artery Occlusive Disease
Primary: Rate of Major Adverse Clinical Events (MACE) — 0.153 MACE events per 9 months
N/A N=10 Improving Walking in Peripheral Artery Disease
Peripheral Artery Disease
Primary: Changes in Walking Distance After Three-months Intervention — 289.68; 262.95 meters
N/A N=40 PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation Clinical Study
Aortoiliac Aneurysms · Iliac Aneurysms
Primary: Number of Patients With Freedom From Patency-related Intervention Defined as a Secondary Intervention to Treat a > 60 % Stenosis of the Internal Iliac Artery Associated…